Video

Dr. Langmuir Discusses Vandetanib Clinical Trials

Author(s):

Peter Langmuir, MD

eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses a phase III double-blind study that investigated the use of vandetanib for 331 patients with unresectable locally advanced or metatastic medullary thyroid cancer.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Related Content
Glenn J. Hanna, MD, director of the Center for Cancer Therapeutic Innovation (Early Drug Development Program), director of Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute; and an associate professor of medicine Harvard Medical School
December 5th 2024

PYX-201 Generates Responses and Contributes to Growing ADC Use in Solid Tumors

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
September 2nd 2021

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Toripalimab Plus Chemo for Nasopharyngeal Carcinoma and ESCC | Image Credit: © Cornflakesei - stock.adobe.com
November 18th 2024

Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC

Versamune HPV in HPV16-Driven HNSCC ©stock.adobe.com
November 18th 2024

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC